Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Krishna Institute of Medical Sciences Limited (KIMS.NS)
Secunderabad, IN
Krishna Institute of Medical Sciences Limited, known by its brand KIMS Hospitals across India, delivers a broad spectrum of medical and healthcare services. The institution boasts a comprehensive array of specialized fields, including cardiology, dentistry, neurology, oncology, orthopedics, nephrology, reproductive medicine, and robotic surgeries. Additionally, it offers expertise in gastroenterology, hepatology, heart and lung transplantation, general organ transplantation, maternal and pediatric care. Other key areas of focus include emergency and accident services, biochemistry, anesthesiology, bariatric surgery, andrology and infertility treatments, arthroscopy, Alzheimer's care, and dedicated bone and joint centers. Founded in 1973, the company is headquartered in Secunderabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.94% | +6.74% | +12.29% | +7.89% | +13.31% | +25.86% | +18.74% | +150.25% | +284.17% | +284.17% | +284.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+30.0% ★ Q1'26: +40.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-37.3% Q1'26: -58.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+1.9% Q1'26: -43.6% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+13.3% ★ Q1'26: +11.3% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+5.6% Q1'26: +4.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×5.30× Q1'26: 5.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 15 Rev. Ana. 11 EPS Ana. |
Mar 2027 15 Rev. Ana. 14 EPS Ana. |
Mar 2028 15 Rev. Ana. 14 EPS Ana. |
Mar 2029 11 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
16.51B
est: 16.55B (-0.2%)
|
21.68B
est: 22.01B (-1.5%)
|
24.74B
est: 25.81B (-4.1%)
|
30.04B
est: 30.29B (-0.8%)
|
38.68B
37.26B – 39.41B
+27.7% YoY
|
49.49B
45.39B – 53.05B
+28.0% YoY
|
60.28B
54.88B – 67.64B
+21.8% YoY
|
56.56B
51.66B – 62.18B
-6.2% YoY
|
| EBITDA |
5.46B
est: 4.72B (+15.5%)
|
6.43B
est: 6.28B (+2.4%)
|
6.52B
est: 7.07B (-7.8%)
|
8.24B
est: 8.30B (-0.8%)
|
10.60B
10.22B – 10.81B
+27.7% YoY
|
13.57B
12.44B – 14.54B
+28.0% YoY
|
16.53B
15.05B – 18.54B
+21.8% YoY
|
15.50B
14.16B – 17.05B
-6.2% YoY
|
| EBIT |
4.73B
est: 3.82B (+23.8%)
|
5.14B
est: 5.08B (+1.2%)
|
5.06B
est: 5.56B (-8.9%)
|
6.47B
est: 6.52B (-0.8%)
|
8.33B
8.02B – 8.49B
+27.7% YoY
|
10.65B
9.77B – 11.42B
+28.0% YoY
|
12.98B
11.82B – 14.56B
+21.8% YoY
|
12.17B
11.12B – 13.39B
-6.2% YoY
|
| Net Income |
3.33B
est: 3.51B (-5.1%)
|
3.36B
est: 3.47B (-3.1%)
|
3.10B
est: 3.16B (-1.9%)
|
3.85B
est: 3.77B (+2.1%)
|
3.29B
2.75B – 3.82B
-12.7% YoY
|
5.11B
4.24B – 6.07B
+55.3% YoY
|
7.56B
6.22B – 9.88B
+48.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
205.01M
est: 2.19B (-90.6%)
|
352.46M
est: 2.91B (-87.9%)
|
495.00M
est: 2.46B (-79.9%)
|
477.00M
est: 2.89B (-83.5%)
|
3.69B
3.56B – 3.76B
+27.7% YoY
|
4.73B
4.33B – 5.07B
+28.0% YoY
|
5.76B
5.24B – 6.46B
+21.8% YoY
|
5.40B
4.93B – 5.94B
-6.2% YoY
|
| EPS |
8.38
est: 8.76 (-4.4%)
|
8.41
est: 9.14 (-7.9%)
|
7.75
est: 7.90 (-1.8%)
|
9.61
est: 9.54 (+0.7%)
|
7.68
6.88 – 9.54
-19.5% YoY
|
13.29
10.59 – 15.16
+73.0% YoY
|
19.48
15.55 – 24.69
+46.6% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree True Emerging Markets Fund XC | 0.05% | 38.8K | 0.32% |
| 2 | WisdomTree India Earnings Fund EPI | 0.03% | 683.4K | 0.84% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bhaskara Rao Bollineni | Founder, MD & Executive Chairman | 45M | — |
| Abhinay Bollineni | Chief Executive Officer & Executive Director | 26M | — |
| Sachin Ashok Salvi | Chief Financial Officer | 15M | male |
| Anitha Dandamudi | Director of Operations & Wholetime Executive Director | 7M | female |
| Juttur Raghavendradas Nagajayanthi | Company Secretary, Compliance Officer & General Counsel | 1M | — |
| Nitish Shetty | CEO for KIMS Bangalore Cluster | — | — |
| Sreenath Pocha Reddy | Cluster Head for the Karnataka cluster | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KIMS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
